← Leaderboards
Premlata Shankar
Immune Disease Institute, Inc.
$5,667,406
Attributed
$5,869,517
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $736.1K · FY2005–15$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$5,869,517 · 8
By mechanism
R01$4,050,557 · 3
R21$1,674,060 · 4
R29$144,900 · 1
Top collaborators
- Haoquan Wu2 shared
Most similar at Immune Disease Institute, Inc.
Same institution · by research overlap
- Manjunath Narasimha Swamy$5,850,104
Others in their field
Top investigators on “Hiv Infections”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,259,079
- Lawrence Corey · Fred Hutchinson Cancer Center$728,701,834
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$467,263,656
- Judith S. Currier · University Of California Los Angeles$466,447,923
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
Research focus
Hiv InfectionsCellsBinding (Molecular Function)BaseT-LymphocyteMouse ModelRna InterferenceMediatingIn VivoViralMutationGenesInfectionIn VitroTargeted DeliveryVirusMouse StrainsReagentAntibodiesLeukocytesMacrophageResponseInterleukin 2 Receptor GammaProteins
Grant awards (18)
Role of PD-1H mediated monocyte activation in HIV pathogenesis$371,837
R01 · FY2015 · HL · contact PI
Role of PD-1H mediated monocyte activation in HIV pathogenesis$377,500
R01 · FY2014 · HL · contact PI
RNAi manipulations of DC to enhance HIV immunogenicity$344,525
R01 · FY2013 · AI · contact PI
HIV protection by ZFN-based disruption of CCR5 gene in Hematopoietic stem cells$215,628
R21 · FY2013 · HL · contact PI
RNAi manipulations of DC to enhance HIV immunogenicity$366,438
R01 · FY2012 · AI · contact PI
HIV protection by ZFN-based disruption of CCR5 gene in Hematopoietic stem cells$188,594
R21 · FY2012 · HL · contact PI
RNAi manipulations of DC to enhance HIV immunogenicity$366,363
R01 · FY2011 · AI · contact PI
RNAi manipulations of DC to enhance HIV immunogenicity$369,990
R01 · FY2010 · AI · contact PI
Targeted delivery of anti HIV sRNAs/shRNAs to T cells$346,841
R01 · FY2010 · AI · contact PI
RNAi manipulations of DC to enhance HIV immunogenicity$385,780
R01 · FY2009 · AI · contact PI
Targeted delivery of anti HIV sRNAs/shRNAs to T cells$350,344
R01 · FY2009 · AI · contact PI
Targeted delivery of anti HIV sRNAs/shRNAs to T cells$362,238
R01 · FY2008 · AI · contact PI
Targeted delivery of anti HIV sRNAs/shRNAs to T cells$408,701
R01 · FY2007 · AI · contact PI
Enhancing HIV-specific CTL by CD27/CD70 costimulation$276,838
R21 · FY2006 · AI · contact PI
Enhancing HIV-specific CTL by CD27/CD70 costimulation$283,500
R21 · FY2005 · AI
EFFECTOR/MEMORY CD8 T CELL FUNCTIONS IN HIV INFECTION$425,700
R21 · FY2001 · AI
CTL LYSIS OF HIV-INFECTED CD4 T CELLS AND MACROPHAGES$283,800
R21 · FY2000 · AI
CTL RECOGNITION OF DOMINANT AND CRYPTIC HIV-1 EPITOPES$144,900
R29 · FY2000 · AI